BioPharmetics, Inc. BPMT) announced the company has increased sales dramatically into South Africa
through their distributor, Destiny Cosmetics. The company recently received
a high 5-figure order with several more scheduled over the next 4 months.
"The market in South Africa is starting to show tremendous promise for the
company," stated Mr. Paul D. Lisenby, CEO of BioPharmetics, Inc. Mr.
Lisenby goes on to say, "The work Destiny Cosmetics and Ms. Fenella Lambert
has done is truly remarkable. Our products have been featured in Heat,
Essentials, and Absolute Nails magazines over the past several months. This
has brought the company's products an exceptional amount of exposure which
translates into sales. We fully expect the South African market to bring in
upwards of $500,000 in sales this year and possibly more. Destiny Cosmetics
is in preliminary talks with several of the largest retail chains in the
country to carry our products on a national level. This could propel our
sales to over $1 million."
For more information about all of BioPharmetics, Inc. products, please
visit the website at www.biopharmetics.com
About BioPharmetics, Inc. (OTC: BPMT)
BioPharmetics, Inc. is a manufacturer and distributor of quality
pharmaceutical, cosmetic, and anti-aging products. The company has three
divisions: biotechnology, pharmaceuticals, and cosmetics/cosmeceuticals,
working in unison to develop, manufacture, and distribute, high-quality
products in the retail, wholesale, and professional markets. Brands
currently offered include Toma(TM), Isseo(TM), Molo Africa(TM), Micha(TM),
and Natural Angel(TM). BioPharmetics, Inc. also private labels many brands
of cosmetics and Cosmeceuticals for salons and retail stores as well as
compounding specialized prescriptions for doctors nationwide.
Safe Harbor
This press release contains or may contain forward-looking statements such
as statements regarding the Company's growth and profitability, growth
strategy, liquidity and access to public markets, operating expense
reduction, and trends in the industry in which the Company operates. The
forward-looking statements contained in this press release are also subject
to other risks and uncertainties, including those more fully described in
the Company's filings with the Securities and Exchange Commission. The
Company assumes no obligation to update these forward-looking statements to
reflect actual results, changes in risks, uncertainties or assumptions
underlying or affecting such statements, or for prospective events that may
have a retroactive effect.
Contact:
FutureTechIR for BioPharmetics
Investor Relations
(817) 812-2105 or 727-417-9338
A True Wise Person Realizes How Much They DON’T Know, Rather Than How Much They DO..
